These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 23551568)

  • 1. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
    Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
    BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
    Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer.
    Kotecha R; Yamada Y; Pei X; Kollmeier MA; Cox B; Cohen GN; Zaider M; Zelefsky MJ
    Brachytherapy; 2013; 12(1):44-9. PubMed ID: 22831750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience.
    Zelefsky MJ; Chou JF; Pei X; Yamada Y; Kollmeier M; Cox B; Zhang Z; Schechter M; Cohen GN; Zaider M
    Brachytherapy; 2012; 11(4):245-9. PubMed ID: 21925957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
    Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
    Zebentout O; Apardian R; Beaulieu L; Harel F; Martin AG; Vigneault E
    Cancer Radiother; 2010 Jun; 14(3):183-8. PubMed ID: 20418145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.
    Khaksar SJ; Laing RW; Henderson A; Sooriakumaran P; Lovell D; Langley SE
    BJU Int; 2006 Dec; 98(6):1210-5. PubMed ID: 17034501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.
    Koontz BF; Chino J; Lee WR; Hahn CA; Buckley N; Huang S; Kim J; Reagan R; Joyner R; Anscher MS
    Brachytherapy; 2009; 8(2):191-196. PubMed ID: 19433320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.
    Langley SEM; Soares R; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Khaksar S; Laing R
    BJU Int; 2018 Jan; 121(1):38-45. PubMed ID: 28670842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
    Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
    Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term potency preservation following brachytherapy for prostate cancer.
    Snyder KM; Stock RG; Buckstein M; Stone NN
    BJU Int; 2012 Jul; 110(2):221-5. PubMed ID: 22734475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.